Innovation Prioritised in Overhaul of Drugs and Medical Device Sectors

Moves have been announced to restructure China’s pharmaceuticals and medical device sectors as a means of promoting greater innovation. More specifically, the procedures for managing clinical trials are to be overhauled, while the approval process for the launch of new products is to be streamlined. Additionally, greater pharmaceutical innovation and the further development of generic drugs are to be prioritised, while greater emphasis is to be placed on both extending the oversight of drugs and medical devices throughout their useful lifespan and improving the technological capabilities of all related industries.

These changes were jointly announced by the General Office of the Chinese Communist Party Central Committee and the General Office of the State Council in the recently-published Opinions on Deepening the Reform of the Evaluation and Approval System and Encouraging Innovation with regards to Drugs and Medical Devices.

For further details (in Chinese), please refer to the following link:

Opinions on Deepening the Reform of the Evaluation and Approval System and Encouraging Innovation with regards to Drugs and Medical Devices